Drug Profile


Alternative Names: MSI-190; MSI-195; SAMe; Strada

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator MSI Methylation Sciences
  • Class Amino acids; Antidepressants; Nootropics
  • Mechanism of Action Beta adrenergic receptor modulators; Biogenic monoamine uptake modulators; Cytokine modulators; Muscarinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 06 Sep 2016 MSI Methylation Sciences plans a pivotal phase III programme for Major depressive disorder (Adjunctive treatment) in USA, European Union and Japan (MSI Methylation Sciences pipeline, September 2016)
  • 27 Jan 2016 Efficacy and adverse events data from the phase II trial in Major depressive disorder released by MSI Methylation Sciences
  • 25 Aug 2015 MSI Methylation Sciences has patent protection for Ademetionine in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top